<DOC>
<DOCNO>EP-0648769</DOCNO> 
<TEXT>
<INVENTION-TITLE>
12-Hetero-substituted 6,11-ethano-6,11-dihydrobenzo¬b quinolizium salts and compositions and method of use thereof
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31435	A61K31435	A61P900	A61P910	A61P2500	A61P2500	A61P2528	C07D45500	C07D45503	C07D47100	C07D47118	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	A61P25	A61P25	A61P25	C07D455	C07D455	C07D471	C07D471	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
12-Hetero substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

salts, pharmaceutical compositions 
containing them, and methods for the treatment or 

prevention of neurodegenerative disorders or neurotoxic 
injuries utilizing them. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
STERLING WINTHROP INC
</APPLICANT-NAME>
<APPLICANT-NAME>
STERLING WINTHROP INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DEHAVEN-HUDKINS DIANE LOUISE C
</INVENTOR-NAME>
<INVENTOR-NAME>
EARLEY WILLIAM GEORGE C O STER
</INVENTOR-NAME>
<INVENTOR-NAME>
KUMAR VIRENDRA C O STERLING WI
</INVENTOR-NAME>
<INVENTOR-NAME>
MALLOMO JOHN PETER C O CEPHALO
</INVENTOR-NAME>
<INVENTOR-NAME>
MILLER MATTHEW STEVEN C O STER
</INVENTOR-NAME>
<INVENTOR-NAME>
DEHAVEN-HUDKINS, DIANE LOUISE, C/O STERLING
</INVENTOR-NAME>
<INVENTOR-NAME>
EARLEY, WILLIAM GEORGE, C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
KUMAR, VIRENDRA, C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
MALLOMO, JOHN PETER, C/O CEPHALON INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
MILLER, MATTHEW STEVEN, C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
The invention relates to 12-hetero substituted 
6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, to 
compositions containing the same, to the method of use 
thereof in the treatment or prevention of neurodegenerative 
disorders or neurotoxic injuries and to a 
process for preparing intermediates. Fields, U.S. Patent 3,517,073 discloses 
compounds of the formula: 
wherein each of R¹, R², R³ and R⁴ when taken separately, 
is hydrogen, lower alkyl, lower aryl, lower acyloxy, 
lower alkoxy, nitro, halogen, lower acylamino, di(lower 
alkyl) amino; one group of R¹ and R², R² and R³, and R³ 
and R⁴, preferably R¹ and R², and R³ and R⁴, each group 
when taken together, represents a fused ring system 
containing up to three 6- member carbocyclic and 
nitrogen-containing heterocyclic rings at least one of 
which is an aromatic ring, and having no more than two 
nuclear nitrogens in any ring, which may be 
unsubstituted or substituted with one or more of the 
substituents defined by R¹, R², R³ and R⁴; each of R⁵ 
and R⁶, when taken separately is hydrogen, lower alkyl 
or lower aryl; each of R⁷ and R⁸, when taken separately, 
is hydrogen; R⁷ and R⁸, when taken together, represent a  
 
fused ring system as defined hereinbefore; R⁹, when 
taken individually, is methylene or lower alkyl, lower 
aryl, lower alkenyl, halogen, or cyano substituted 
methylene; R¹⁰, when taken individually, is a protected 
carbonyl group; R⁹ and R¹⁰, when taken together, 
represent a fused aromatic carbocyclic or heterocyclic 
ring system, whose valence bonds are from adjacent 
carbons, containing up to three 6-membered carbocyclic 
and nitrogen-containing heterocyclic rings having no 
more than two nitrogens in any ring and which may be 
substituted with one or more of the substituents defined 
by R¹, R², R³ and R⁴. Among the compounds specifically 
disclosed are 12,12-diethoxy-11-methyl-9,10-ethano-9,10-dihydro-4a-azoniaanthracene 
perchlorate and 
9,10-(O-benzeno)-9,10-dihydro-5-methyl-4a-azoniaanthracene 
perchlorate. Also disclosed are compounds of 
the formula: 
wherein R¹-R¹⁰ are as defined above and m is an odd 
integer having a value of from 1 to 5, inclusive. Among 
the compounds specifically disclosed are 12,12-diethoxy-11-methyl-9,10-ethano-4a-aza-1,2,3,4,4a,9,9a,10-octahydroanthracene 
perchlorate acid salt, 9,10-(O-benzeno)-5-methyl-4a-aza-1,2,3,4,4a,9,9a,10-octahydroanthracene 
and 12,12-diethoxy-9,10-ethano-11-bromo-4a-aza-1,2,3,4,4a,9,9a,10-octahydroanthracene. 
The above-described 
compounds are disclosed as being
</DESCRIPTION>
<CLAIMS>
1. A compound of the formula: 
 

wherein: 
   R¹ is hydrogen, or from one to four, the same or 

different, substituents in any of the 
1-, 2-, 3-, or 4-positions selected from the group 

consisting of lower-alkoxy, lower-alkyl, and halogen; 
   R² is hydrogen, or from one to four, the same or 

different, substituents in any of the 
7-, 8-, 9-, or 10-positions selected from the group 

consisting of lower-alkyl, lower-alkanoyloxy, halogen, 
nitro, hydroxy, lower-alkoxy, methylenedioxy, 

polyfluorolower-alkyl and polychlorolower-alkyl; 
   R³ and R⁴ are the same or different lower-alkyl; 

   R⁵ and R⁶ are independently selected from the 
group consisting of hydrogen, lower-alkoxy, trilower-alkylsilyloxy 

and dilower-alkylamino; or 
   R⁵ and R⁶ together represent 

-O-CHR⁸(CH₂)nCHR⁹-O- wherein n is zero or one and 
R⁸ and R⁹ are independently hydrogen, lower-alkyl, or 

phenyl-lower-alkoxy-lower-alkyl; 
   R⁷ is hydrogen, or lower-alkyl; and 

   X⁻ is an anion; 
or a pharmaceutically acceptable acid-addition salt of 

basic members thereof; or a hydrate thereof; or a 
stereoisomer thereof;

 
with the proviso that when R¹, R² and R⁷ are hydrogen, 

R³ and R⁴ are methyl and X⁻ is ClO₄⁻, R⁵ and R⁶ together 
cannot be -O-CH(CH₃)CH(CH₃)-O- or simultaneously 

methoxy; further provided that R⁵ and R⁶ together cannot 
both simultaneously be hydrogen. 
2. A compound according to claim 1 wherein: 
   R¹ is hydrogen, or one substituent in any of the 

1-, 2-, 3- or 4-positions selected from the group 
consisting of lower-alkoxy, lower-alkyl and halogen; and 

   R² is hydrogen, or from one to two, the same or 
different, substituents in any of the 

7-, 8-, 9-, or 10-positions selected from the group 
consisting of lower-alkyl, lower-alkanoyloxy, halogen, 

nitro, hydroxy, lower-alkoxy, methylenedioxy, 
polyfluorolower-alkyl and polychlorolower-alkyl. 
3. A compound according to claim 2 wherein: 
   R¹ is hydrogen, or one substituent in any of the 

1-, 2-, 3- or 4-positions selected from the group 
consisting of lower-alkoxy, and lower-alkyl; 

   R² is hydrogen, or from one to two, the same or 
different, substituents in any of the 

7-, 8-, 9- or 10-positions selected from the group 
consisting of lower-alkyl, lower-alkanoyloxy, halogen, 

nitro, hydroxy, lower-alkoxy, methylenedioxy, and 
polyfluorolower-alkyl; and 

   R³ and R⁴ are the same lower-alkyl. 
4. A compound according to claim 3 wherein: 
   R¹ is hydrogen, 1-lower-alkoxy, or 4-lower-alkyl; 

and 
   R² is hydrogen, or from one to two, the same or 

different, substituents in any of the 
7-, 8-, 9- or 10-positions selected from the group 

consisting of lower-alkyl, acetoxy, halogen, nitro, 
hydroxy, lower-alkoxy, methylenedioxy and 

trifluoromethyl. 
5. A compound according to claim 4 wherein 
   R¹ is hydrogen, 1-methoxy or 4-methyl; and 

   R² is hydrogen, or from one to two, the same or 
different, substituents in any of the 

7-, 8-, 9- or 10-positions selected from the group 
consisting of methyl, tert-butyl, acetoxy, bromine, 

chlorine, fluorine, nitro, hydroxy, methoxy, isopropoxy, 
methylenedioxy and trifluoromethyl. 
6. A compound according to claim 5 wherein 
R³ and R⁴ are both methyl or ethyl; and R⁷ is hydrogen 

or methyl. 
7. A compound according to claim 6 wherein 
   R⁵
 and R⁶ are independently selected from the 
group consisting of hydrogen, lower-alkoxy, 

trimethylsilyloxy and diethylamino; or 
   R⁵ and R⁶ together represent -OCHR⁸(CH₂)nCHR⁹-O-wherein 

n is zero or one and 
R⁸ and R⁹ are simultaneously hydrogen, lower-alkyl or 

phenyl-lower-alkoxy-lower-alkyl. 
8. A compound according to claim 7 wherein 
   R⁵ and R⁶ are independently selected from the 

group consisting of hydrogen, methoxy, ethoxy, propoxy, 
trimethylsilyloxy, and diethylamino; or 

   R⁵ and R⁶ together represent -OCHR⁸(CH₂)nCHR⁹-O-wherein 
n is zero or one and 

R⁸ and R⁹ are simultaneously hydrogen, methyl, or 
phenylmethoxymethyl. 
9. A compound according to claim 8 selected from 
the group consisting of: 

   12,12-dipropoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

X⁻; 
   11-methyl-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
X⁻; 

   9-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

X⁻;
 

   10-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

X⁻; 
   12,12-diethoxy-13,13-diethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
X⁻; and 

   12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

X⁻. 
10. A compound according to claim 9 selected from 
the group consisting of: 

   12,12-dipropoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

perchlorate; 
   11-methyl-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
perchlorate; 

   11-methyl-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

chloride; 
   9-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium·PF₆⁻; 
   9-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
chloride; 

   10-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

perchlorate; 
   10-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
chloride; 

   12,12-diethoxy-13,13-diethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

perchlorate; and 
   12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
X⁻, wherein 

X⁻ is ClO₄⁻, Cl⁻, PF₆⁻, [(-)-DBT]⁻, [(+)-DBT]
⁻, (S)-(+)-CH₃C(Ph)(OH)CO₂⁻, 
or (1S)-(-)-C₁₀H₁₃O₄⁻. 
11. 9-Methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium·PF₆⁻. 
12. 10-Methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

chloride . 
14. A compound of the formula: 
 

wherein: 
   R³ and R⁴ are independently hydrogen, lower-alkoxy, 

or chlorine; 
   R⁵ and R⁶ are the same or different lower-alkoxy; 

and 
   X⁻ is an anion; 

or a stereoisomer thereof; with the proviso that R³ and 
R⁴ cannot both simultaneously be hydrogen. 
15. A compound according to claim 14 wherein 
R³ and R⁴ are independently hydrogen, ethoxy, or 

chlorine; and R⁵ and R⁶ are the same lower-alkoxy. 
16. A compound according to claim 15 wherein 
R⁵ and R⁶ are ethoxy. 
17. A compound according to claim 16 wherein 
R³ is chlorine, R⁴ is hydrogen, R⁵ and R⁶ are ethoxy and 

X⁻ is Br⁻; or R³ is hydrogen, R⁴ is chlorine, R⁵ and R⁶ 
are ethoxy and X⁻ is ClO₄⁻. 
18. 12,12,13,13-tetraethoxy-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

perchlorate. 
19. A compound of the formula: 
 

wherein: 
   R³ and R⁴ are independently hydrogen, or lower-alkyl; 

   R⁵ and R⁶ are independently hydrogen, or 
dilower-alkylamino; and 

   X⁻ is an anion; 
or a pharmaceutically acceptable acid-addition salt of 

basic members thereof; or a stereoisomer thereof; 
with the proviso that R³ and R⁴ cannot simultaneously be 

lower-alkyl; further provided that R⁵ and R⁶ cannot 
simultaneously be hydrogen. 
20. A compound according to claim 19 wherein 
R³ and R⁴ are independently hydrogen or methyl; and 

R⁵ and R⁶ are independently hydrogen or diethylamino. 
21. 12-diethylamino-13-methyl-6,11-ethano-6,11-dihydrobenzo[b]quinolizinium 

perchlorate. 
22. A pharmaceutical composition which comprises a 
compound of the formula: 

 
wherein:

 
   R¹, R², R⁵, R⁶, R⁷ and X⁻ are as defined in 

claim 1, subject to the proviso below, and 
   R³ and R⁴ are independently selected from the 

group consisting of hydrogen, lower-alkoxy, halogen, 
lower-alkyl, and phenyl; 

   or a pharmaceutically acceptable acid-addition 
salt of basic members thereof; or a hydrate thereof; or 

a stereoisomer thereof; together with a pharmaceutically 
acceptable carrier, adjuvant, diluent or vehicle; with 

the proviso that when R¹, R³, R⁴, and R⁷ are hydrogen, 
R⁵ and R⁶ are ethoxy and X⁻ is ClO₄⁻, 

R² cannot be 7,10-diacetoxy or 7-acetoxy-10-tert-butyl; 
further provided that when R¹, R² and R⁷ are hydrogen, 

R³ and R⁴ are methyl and X⁻ is ClO₄⁻, R⁵ and R⁶ together 
cannot be -O-CH(CH₃)CH(CH₃)-O-; still further provided 

that when R¹, R⁴, R⁵ and R⁷ are hydrogen, R³ and R⁶ are 
ethoxy and X⁻ is ClO₄⁻, R² cannot be 7-NO₂; still 

further provided that R⁵ and R⁶ cannot both 
simultaneously be hydrogen. 
23. A pharmaceutical composition according to 
claim 22 wherein: 

   R¹ and R² are as defined in any one of claims 
3 to 5. 
24. A pharmaceutical composition according to 
claim 23 wherein R³ and R⁴ are independently selected 

from the group consisting of hydrogen, ethoxy, bromine, 
chlorine, methyl, ethyl and phenyl; and R⁷ is hydrogen 

or methyl. 
25. A pharmaceutical composition according to 
claim 24 wherein R⁵ and R⁶ are defined as in claim 8 
26. A pharmaceutical composition according to 
claim 23 wherein R³ and R⁴ are the same lower-alkyl. 
27. A pharmaceutical composition according to 
claim 26 wherein R³ and R⁴ are both methyl or ethyl, and 

R⁷ is hydrogen or methyl. 
28. A pharmaceutical composition according to 
claim 27 wherein R⁵ and R⁶ are as defined in claim 8. 
29. A pharmaceutical composition according to 
claim 28 wherein the compound is 9-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium·PF₆⁻. 
30. A pharmaceutical composition according to 
claim 28 wherein the compound is 10-methoxy-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
chloride. 
31. A pharmaceutical composition according to 
claim 28 wherein the compound is (-)-12,12-diethoxy-13,13-dimethyl-6,11-ethano-6,11-dihydrobenzo[b]
quinolizinium 
chloride. 
32. The use of a compound of the formula: 
 

wherein: 
   R¹,R²,R³,R⁴,R⁵,R⁶,R⁷,R⁸,R⁹, n and X⁻ are as 

defined in any one of claims 22 to 31 for the 
preparation of a medicament for the treatment or 

prevention of neurodegenerative disorders or neurotoxic 

injuries in a patient in need of such treatment. 
33. A use according to claim 32 for the treatment 
or prevention of neurotoxic injuries. 
34. A use according to claim 33 wherein said 
neurotoxic injuries are associated with ischemic, 

hypoxic, or hypoglycemic conditions. 
35. A use according to claim 34 wherein said 
ischemic, hypoxic, or hypoglycemic conditions are 

associated with stroke. 
</CLAIMS>
</TEXT>
</DOC>
